![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, July 30, 2023 3:51:06 PM
Michael J. Ambrogi has been appointed as Vice President - Senior Technology Fellow of the Company effective 9/1/2020. He has been our Chief Operating Officer since 2010 and previously served as our U.S. General Manager from 2006 to 2010. Mr. Ambrogi has overall responsibility for our ongoing operations, engineering, manufacturing, service and human resources activities worldwide.
Asaf Danziger has served as Chief Executive Officer of Novocure since 2002 and has been a director of Novocure since 2012. Mr. Danziger has led the company and the development of TTFields therapy from preclinical testing through regulatory approvals to commercial sales in Europe and the United States.
Charles G. Phillips III has been a director of Novocure since 2012 and has served on our audit committee and as the chairperson of our compensation committee since 2012.
Mr. Doyle has served as our Executive Chairman since 2016, as Chairman of the Board since 2009 and as a member of our Board of Directors since 2004.
Dr. Eilon Kirson joined Novocure in 2002 and served as Chief Medical Officer until 2012 when he was promoted to Chief Science Officer and Head of Research and Development.
Dr. Ely Benaim joined Novocure in April 2019 and serves as Chief Medical Officer.
Frank Leonard has served as Novocure’s Chief Development Officer since September 2020. This newly created executive role has responsibility for engineering, product development, business development, and the overall strategic and operational leadership of Novocure’s innovation platforms.
Gabriel Leung has been Vice Chairman and a director of Novocure since 2011.
Todd Longsworth joined Novocure in 2012 and serves as General Counsel.
Wilco Groenhuysen has served as Novocure’s Chief Operating Officer since September 2020. He is responsible for the general and administrative management of the company, the strategic and operational leadership of Novocure’s supply chain, warehousing and distribution, quality assurance and information technology operations. Mr. Groenhuysen is tasked to ensure organizational readiness in anticipation of the completion of four phase 3 clinical trials over the next few years.
![](http://investorshub.advfn.com/uimage/uploads/2023/7/30/zdnysAmbrogi_NVCR.png)
https://investorshub.advfn.com/uimage/uploads/2023/7/30/iqylhAsaf_Danziger_NVCR.png
![](http://investorshub.advfn.com/uimage/uploads/2023/7/30/zvvrpCharles_Phillips_NVCR.png)
![](http://investorshub.advfn.com/uimage/uploads/2023/7/30/vhkosDoyle_NVCR.png)
![](http://investorshub.advfn.com/uimage/uploads/2023/7/30/cqjzsEilon_Kirson_NVCR.png)
![](http://investorshub.advfn.com/uimage/uploads/2023/7/30/hgnxtEly_Benaim_NVCR.png)
![](http://investorshub.advfn.com/uimage/uploads/2023/7/30/jrbezFrank_Leonard_NVCR.png)
![](http://investorshub.advfn.com/uimage/uploads/2023/7/30/aoylbGabriel_Leung_NVCR.png)
![](http://investorshub.advfn.com/uimage/uploads/2023/7/30/nwivnTodd_Longsworth_NVCR.png)
![](http://investorshub.advfn.com/uimage/uploads/2023/7/30/gpqbsWilhelmus_Groenhuysen_NVCR.png)
Recent NVCR News
- Novocure to Participate in 2024 Wells Fargo Healthcare Conference • Business Wire • 08/28/2024 11:00:00 AM
- Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer • Business Wire • 08/14/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2024 08:22:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2024 08:19:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2024 08:19:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2024 08:17:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2024 08:16:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 08:25:19 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 07/25/2024 12:25:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/25/2024 11:05:37 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 11:01:22 AM
- Novocure Reports Second Quarter 2024 Financial Results • Business Wire • 07/25/2024 11:00:00 AM
- Novocure to Report Second Quarter 2024 Financial Results • Business Wire • 07/01/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:09:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 10:37:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 10:13:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 09:43:31 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM